Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Fondazione EMN Italy Onlus
- Target Recruit Count
- 402
- Registration Number
- NCT00551928
- Locations
- 🇮🇹
Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy
Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT00546897
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
- Conditions
- Interventions
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT00543114
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
- First Posted Date
- 2007-10-05
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 80
- Registration Number
- NCT00540007
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-10-03
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 5
- Registration Number
- NCT00538824
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-10-03
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 26
- Registration Number
- NCT00538733
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 64
- Registration Number
- NCT00536341
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸National Capital Clinical Research Consortium, Bethesda, Maryland, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
- Conditions
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT00535873
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00525447
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
- Conditions
- Interventions
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00522392
- Locations
- 🇺🇸
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States
🇺🇸Illinois Oncology Research Association CCOP, Peoria, Illinois, United States
🇺🇸Saint Francis Hospital and Health Centers, Beech Grove, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.